Congressional Ban Threatens Medicare and Medicaid Hemp Reimbursement Pilot
A recent congressional action to ban hemp could jeopardize a new pilot program designed to reimburse Medicare and Medicaid recipients for hemp-derived products.
By The Herb House Desk·May 17, 2026
A congressional ban enacted in November may undermine a recently launched pilot program by the Centers for Medicare and Medicaid Services (CMS).
This new CMS initiative aims to reimburse eligible Medicare and Medicaid patients for up to $500 annually in hemp-derived products, including CBD. The program's design includes an evaluation of whether these products can lead to a reduction in other health-related expenses for participants.
Source: The Guardian.
Reporting informed by public dispatches from The Guardian.